<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813800</url>
  </required_header>
  <id_info>
    <org_study_id>08-003471</org_study_id>
    <nct_id>NCT00813800</nct_id>
  </id_info>
  <brief_title>Varenicline in Bipolar Depressed Patients</brief_title>
  <acronym>Varenicline</acronym>
  <official_title>Varenicline for Smoking Cessation in Bipolar Depressed Patients: An Open-Label 12-week Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Frye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with bipolar disorder have one of the highest rates of nicotine dependence and one&#xD;
      of the lowest quit rates. Varenicline has been shown in previous trials to be effective for&#xD;
      smoking cessation, but has not been studied in subjects with bipolar disorder. This 12-week&#xD;
      open label trial will be conducted to assess the feasibility, acceptability, and safety of&#xD;
      varenicline in bipolar depressed smokers, given in addition to the subject's primary&#xD;
      treatment for bipolar disorder. The primary study hypothesis was that the abstinence rate for&#xD;
      bipolar depressed patients will be 50%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Varenicline, a nicotinic acetylcholine receptor partial agonist, has been shown in two&#xD;
      placebo-controlled trials to be efficacious for smoking cessation. Given the high prevalence&#xD;
      of nicotine dependence in bipolar disorder and the high prevalence of sub-syndromal and&#xD;
      syndromal depressive symptoms in bipolar disorder, this 12-week adjunctive varenicline open&#xD;
      label trial will be conducted to assess the feasibility, acceptability, and safety of&#xD;
      varenicline in bipolar depressed smokers. All subjects will receive individual behavioral&#xD;
      counseling.&#xD;
&#xD;
      Primary hypothesis: the abstinence rate for bipolar depressed patients will be 50%. Secondary&#xD;
      hypothesis: At final visit, bipolar depressed patients who have achieved remission, defined&#xD;
      as a Montgomery Asberg Depression Rating Scale (MADRS) &lt;8, will have a higher rate of tobacco&#xD;
      abstinence than depressed patients who did not achieve remission (MADRS &gt;/= 8).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carbon Monoxide Breath Level at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by expired breath in parts per million (ppm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item on the MADRS is scaled 0 through 6. Lowest score = 0, would indicate no depressive symptoms. Highest score = 60, indicating extreme depression. MADRS score &gt; 20 is syndromal depression. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>YMRS is an eleven-item, multiple choice diagnostic questionnaire which psychiatrists use to measure the severity of manic episodes in patients already diagnosed with mania. Lowest score = 0, normal subject; Highest score = 60, highly manic subject. For this scale the following scores are associated with these grades of severity: mania (YMRS = 20), hypomania (YMRS = 12), under 5 is classified as non-manic. Young RC, Biggs JT, Ziegler Ve, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. BR J Psychiatry 1978; 133:429-435.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Smoking</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label; subjects will receive a behavioral intervention in addition to Varenicline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 -65 years&#xD;
&#xD;
          -  Meet DSM-IV criteria for bipolar disorder type I or II and nicotine dependence&#xD;
&#xD;
          -  DSM-IV confirmed current major depressive episode OR current depressive symptoms&#xD;
             defined as MADRS &gt; 4 &amp; &lt;20&#xD;
&#xD;
          -  Smoke at least 10 cigarettes per day&#xD;
&#xD;
          -  Fagerström Test of Nicotine Dependence (FTND) score of 5 or higher&#xD;
&#xD;
          -  Agree to identify collateral individuals for contact purposes to facilitate follow-up&#xD;
             appointments&#xD;
&#xD;
          -  Currently on mood stabilization treatment. A minimum daily therapeutic dosage of at&#xD;
             least one mood stabilizer, and on the same dose for at least 2 weeks:&#xD;
&#xD;
               -  Lithium (0.6-1.2 mEq/L or 900 mg), Valproate (50-125 mg/mL or 1000 mg),&#xD;
                  Carbamazepine (4-12 mg/mL or 800 mg), Oxcarbazepine 1200 mg, Lamotrigine 100 mg,&#xD;
                  Olanzapine 10mg, Risperidone 2mg, Quetiapine 300mg, Ziprasidone 40mg,&#xD;
                  Aripiprazole 7.5 mg&#xD;
&#xD;
               -  Antidepressants are not exclusionary.&#xD;
&#xD;
               -  Topiramate is an acceptable mood stabilization treatment. There is an evidence&#xD;
                  base (Delbello et al. 2005) highlighting efficacy of topiramate monotherapy for&#xD;
                  acute mania in children and adolescents with bipolar disorder type 1.&#xD;
&#xD;
        [Mood stabilizers are a standard American Psychiatric Association (APA) treatment&#xD;
        guidelines for Bipolar I disorder (history of mania). While the guidelines for Bipolar II&#xD;
        disorder are unclear (history of hypomania), we feel mood stabilization provides&#xD;
        standardization of treatment and maximizes safety (ie: preventing switch from depression to&#xD;
        mania or hypomania).]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DSM-IV dependence for a substance other than nicotine or caffeine within past 3&#xD;
             months.&#xD;
&#xD;
          -  DSM-IV criteria of schizophrenia or other non-affective psychotic disorder&#xD;
&#xD;
          -  Psychotic symptoms within the past month&#xD;
&#xD;
          -  Active suicidality as measured by screening questions from the Columbia-Suicide&#xD;
             Severity Rating Scale (C-SSRS&#xD;
&#xD;
          -  History of medically serious suicide attempt as reviewed by doctor.&#xD;
&#xD;
          -  Current use (past 30 days) of other smoking cessation treatments&#xD;
&#xD;
          -  Pregnant or nursing women, or women who refuse to use adequate birth control&#xD;
&#xD;
          -  Serious, active or unstable medical condition&#xD;
&#xD;
          -  Individuals, in the investigators opinion, unable to comply with study procedures&#xD;
&#xD;
          -  Inability to provide written informed consent in English&#xD;
&#xD;
          -  Allergic reaction to varenicline&#xD;
&#xD;
          -  Individuals who are on dialysis or have a history of kidney disease (varenicline is&#xD;
             excreted 96% unchanged through the kidneys) or Creatine supplementation or current&#xD;
             anticipated daily NSAID use&#xD;
&#xD;
          -  Presence of a personality disorder, that upon review of the medical record, appears to&#xD;
             be the primary reason for psychiatric care.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A. Frye, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <results_first_submitted>November 11, 2011</results_first_submitted>
  <results_first_submitted_qc>December 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2012</results_first_posted>
  <last_update_submitted>December 23, 2011</last_update_submitted>
  <last_update_submitted_qc>December 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mark Frye</investigator_full_name>
    <investigator_title>MD, Professor of Psychiatry, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>11 patients were enrolled from the community all with bipolar depression and the desire to stop smoking.</recruitment_details>
      <pre_assignment_details>36 patients who were screened did not meet inclusion/exclusion criteria and excluded from participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>Open-label; subjects will receive a behavioral intervention in addition to Varenicline. Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure after Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening of depression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>Open-label; subjects will receive a behavioral intervention in addition to Varenicline. Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Questionnaire of Smoking Urges (QSU-brief)</title>
          <description>The USU-brief is used as a measure of craving or desire to smoke. It uses 10 &quot;agree-disagree&quot; statements in a rating scale, five covering need to smoke for relief and five covering positive desire to smoke for reward. Maximum score = 1000, indicates a high level of craving. Minimum score = 0, indicates no craving for smoking. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboaratory and clinical setting. Nicotine &amp; Tobacco Research (2001)3(1):7-16.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="476" spread="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes (per day)</title>
          <units>Cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.8" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carbon Monoxide Breath Level</title>
          <description>Measured by expired breath in parts per million (ppm). (0-10 = non smoker; 11-20 = light smoker; &gt;20 = heavy smoker)</description>
          <units>ppm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item on the MADRS is scaled 0 through 6. Lowest score = 0, would indicate no depressive symptoms. Highest score = 60, indicating extreme depression. MADRS score &gt; 20 is syndromal depression. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Young Mania Rating Scale (YMRS)</title>
          <description>YMRS is an eleven-item, multiple choice diagnostic questionnaire which psychiatrists use to measure the severity of manic episodes in patients already diagnosed with mania. Lowest score = 0, normal subject; Highest score = 60, highly manic subject. For this scale the following scores are associated with these grades of severity: mania (YMRS = 20), hypomania (YMRS = 12), under 5 is classified as non-manic. Young RC, Biggs JT, Ziegler Ve, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. BR J Psychiatry 1978; 133:429-435.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Carbon Monoxide Breath Level at 12 Weeks</title>
        <description>Measured by expired breath in parts per million (ppm)</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Open-label; subjects will receive a behavioral intervention in addition to Varenicline. Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Carbon Monoxide Breath Level at 12 Weeks</title>
          <description>Measured by expired breath in parts per million (ppm)</description>
          <population>Intention to Treat (ITT)</population>
          <units>ppm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery-Asberg Depression Rating Scale (MADRS) at 12 Weeks</title>
        <description>MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item on the MADRS is scaled 0 through 6. Lowest score = 0, would indicate no depressive symptoms. Highest score = 60, indicating extreme depression. MADRS score &gt; 20 is syndromal depression. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Open-label; subjects will receive a behavioral intervention in addition to Varenicline. Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS) at 12 Weeks</title>
          <description>MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Each item on the MADRS is scaled 0 through 6. Lowest score = 0, would indicate no depressive symptoms. Highest score = 60, indicating extreme depression. MADRS score &gt; 20 is syndromal depression. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.</description>
          <population>Intention to Treat (ITT)</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Young Mania Rating Scale (YMRS) at 12 Weeks</title>
        <description>YMRS is an eleven-item, multiple choice diagnostic questionnaire which psychiatrists use to measure the severity of manic episodes in patients already diagnosed with mania. Lowest score = 0, normal subject; Highest score = 60, highly manic subject. For this scale the following scores are associated with these grades of severity: mania (YMRS = 20), hypomania (YMRS = 12), under 5 is classified as non-manic. Young RC, Biggs JT, Ziegler Ve, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. BR J Psychiatry 1978; 133:429-435.</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Open-label; subjects will receive a behavioral intervention in addition to Varenicline. Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Young Mania Rating Scale (YMRS) at 12 Weeks</title>
          <description>YMRS is an eleven-item, multiple choice diagnostic questionnaire which psychiatrists use to measure the severity of manic episodes in patients already diagnosed with mania. Lowest score = 0, normal subject; Highest score = 60, highly manic subject. For this scale the following scores are associated with these grades of severity: mania (YMRS = 20), hypomania (YMRS = 12), under 5 is classified as non-manic. Young RC, Biggs JT, Ziegler Ve, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. BR J Psychiatry 1978; 133:429-435.</description>
          <population>Intention to Treat (ITT)</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks per participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>Open-label; subjects will receive a behavioral intervention in addition to Varenicline. Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lack of concentration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Compartmental Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size; limitations finding participants with stable state within their bipolar disorder.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark Frye, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-9391</phone>
      <email>mfrye@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

